Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Lymphoid 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 351pembrolizumab 326Pemetrexed 250Cisplatin 221Paclitaxel 149Nivolumab 139durvalumab 134osimertinib 112Docetaxel 112atezolizumab 109Specimen Handling 91Radiotherapy 88Drug Therapy 87Magnetic Resonance Spectroscopy 77Etoposide 77Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 42Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmacokinetics × Thoracic × 1 year × Clear all
NCT07436858 2026-02-27

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

The Netherlands Cancer Institute

Phase 1 Not yet recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡